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Introduction
Intrauterine growth restriction (IUGR) is a frequent complication of pregnancy, affecting between 3
and 7% of total  population (1).  Even tough its  definition is  still  under consideration,  the most
common criterion is a birth weight below the 10th percentile. However, a birth weight below the 5th
or even the 3th percentile is also sometimes used as a criterion to define IUGR. Furthermore, another
problematic point is that such a definition does not make a difference between growth-restricted
babies and babies who are constitutively small. Therefore it is important to determine whether a
growth curve break occurred in utero, based  on prenatal ultrasonographic measurements, as this
condition would prove IUGR. On the contrary, a constitutively small baby would have harmonious
growth curves, based on his genetic background.
Although the mechanisms leading to IUGR remain poorly understood, its origins are classified into
three groups, depending on their  etiology:  maternal causes (smoke, malnutrition...(2)),  placental
dysfunction or fetal causes (malformations, genetic syndromes, inborn errors of metabolism...). The
consequence  is  either  an  extrinsic  insufficiency  of  oxygen  and  nutrients supply  to  the  fetus
(maternal  causes  and  placental  dysfunction),  or  an  intrinsic  cause  such  as  increase  of  needs,
metabolism deficiency or restricted growth potential (fetal causes).
IUGR  has been recognized to be an important cause of perinatal morbidity and mortality. Many
epidemiological studies have also shown that IUGR can have an important impact on health much
later in life. Indeed, a low birth weight, as it happens in IUGR, has been linked to several frequent
chronic diseases in adulthood, like coronary heart  disease, cardiovascular disease (3), metabolic
syndrome,  diabetes  mellitus  type  II,  stroke  and  osteoporosis  (2,4).  An  explanation  to  these
observations was proposed by the "Barker hypothesis", which stipulates that early development is a
critical time window in which the fetus' nutrition, oxygen supply and the intrauterine environment
in general, can affect the fetal gene expression, leading to a long lasting epigenetic imprint, which
influences metabolism up to adulthood (5,6,7,8,9,10). Structural changes in organogenesis, which
could account for a higher risk to develop chronic diseases, have also been observed in the heart,
the kidney and the pancreas of growth-restricted animals (2).
In order to better understand the development of IUGR, it seems therefore important to focus on the
feto-maternal  exchanges,  in  which  the  placenta  and the  umbilical  cord  play a  major  role.  The
placenta is in charge of transmitting oxygen and nutrients from the mother's to the fetus' blood, and
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the umbilical circulation is the only pathway for this blood to reach the fetus. Therefore, it can
easily be imagined how even small changes in this system could have important consequences on
the fetus' oxygen and nutrient supply. 
Several studies have identified differences in placental and umbilical circulations between growth-
restricted fetuses and controls. Resistance in feto-placental circulation was shown to be increased in
IUGR (11). Since oxygen concentration affects the tone of chorionic plate vessels in the placenta
(12), the decrease in oxygen saturation observed in IUGR umbilical blood (13) could contribute to
this  increased  resistance.  It  is  furthermore  interesting  to  note  that  the  mechanism involved  in
hypoxic feto-placental vasoconstriction, namely a potassium channel inhibition (14), is similar to
the mechanism observed in other oxygen-sensitive tissues, like the lungs (15). Such similarities are
not surprising, since the placenta and the feto-placental circulation assume in utero the role which is
taken over by the lungs after birth, that is the organism's oxygen supply. 
There were also several differences observed between IUGR and control umbilical vessels. Indeed,
IUGR umbilical arteries were shown to have a thinner wall and a stronger contraction than control
umbilical arteries (16). This may be a link to arterial hypertension observed in adulthood, but could
also account for changes in the feto-placental circulation. Other in vitro studies in an ovine model of
IUGR mention that IUGR umbilical arteries constrict less than controls (17). Additionally they also
relax more than controls when exposed to the vasodilating agent bradykinin, but not when exposed
to the nitric oxide (NO) donor sodium nitroprusside (18). This would suggest that only certain
pathways are altered in IUGR umbilical arteries.  But in any case, there seem to be alterations in
IUGR  umbilical  vessels,  which  affect  their  tone  and  their  response  to  vasodilating  or
vasoconstricting stimuli. 
Since several years, a project focused on human umbilical cords in case of growth restriction is
conducted  under  supervision  of  Dr  A.-C.  Peyter  and  Pr  J.-F.  Tolsa  at  the  Neonatal  Research
Laboratory of  the Clinic  of  Neonatology at  the  University Hospital  CHUV in Lausanne.  They
hypothesized that the  decrease  in  oxygen  and/or  nutrient  supply  to  the  fetus,  in  case  of
placental insufficiency, is associated with modifications in pathways involved in the regulation
of  umbilical  vascular  tone,  contributing  to  further  impairment  of  the  fetal-maternal
exchanges and to development of IUGR.
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Pharmacological  studies  showed  that  the  relaxation  induced  by  the  NO  donor  DEA/NO  in
preconstricted  isolated  human umbilical  veins  from IUGR newborns  is  decreased  compared to
controls adapted for gestational age (19).
The aim of the present project was to compare the expression of several specific proteins involved
in the  NO-mediated relaxation in the human umbilical vein between growth-restricted newborns
and controls. In particular, we focused on the following proteins: 
1) Endothelial  nitric  oxide  synthase  (eNOS),  which  is  responsible  for  producing  the
vasodilating agent NO
2) Caveolin, a membrane protein, which regulates the membrane localization and activation of
eNOS
3) Soluble guanylyl  cyclase (sGC), which produces the second messenger cyclic guanosine
monophosphate (cGMP) when stimulated by NO
4) Phosphodiesterase 5a (PDE5a), which degrades cGMP (20) (Illustration 1). 
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Illustration 1: Simplified schema of the NO/cGMP signaling pathway in 
blood vessels. NO: nitric oxide; eNOS: endothelial synthase; sGC soluble
guanylate synthase; cGMP: cyclic guanosine monophosphate; PDE's: 
phosphodiesterases. (Courtesy of Dr Anne-Christine Peyter)
Identification of changes in specific protein expression in umbilical vessels of growth-restricted
newborns could lead to identification of potential therapeutic targets to limit or prevent IUGR, but
also  of  some  biological  markers  to  detect  individuals  with  increased  risk  for  developing
cardiovascular disease in adulthood.
In this project, we decided to focus on the umbilical vein, since this is the only vessel through
which oxygen and nutrients are brought from the placenta to the fetus.  Therefore,  an impaired
function of the umbilical vein affecting its diameter would have a direct influence on the fetus'
oxygen  and  nutrient  supply.  We  limited  our  investigations  to  female  newborns, because
pharmacological studies performed on isolated umbilical veins of newborn boys failed to show any
difference in NO-induced relaxation between IUGR and controls (19). Moreover, IUGR is more
frequent in female fetuses (21,22).
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Material and methods
Umbilical  cords  were  collected  from the  maternity  ward  of  the  Department  of  Obstetrics  and
Gynecology, University Hospital of Lausanne immediately after birth. Exclusion criteria were
• Maternal positive HIV, hepatitis A, B or C serology or unknown serological status
• Preeclampsia complicated pregnancy
• Newborns with malformations or genetic syndromes
• Multiple pregnancy
• Umbilical cord with anatomic variations in form of other status than two arteries and one
vein
• Birth weight over the 90th percentile
The control group and the IUGR  group were defined as follows.  Neonates with a birth weight
between the 10th and 90th percentile (adapted for gestational age)  were attributed to the control
group. Newborns with a birth weight below the 10th  percentile were considered as IUGR. When
available, prenatal data were collected to determine whether a break in the intrauterine growth curve
occurred, in order to confirm IUGR status, versus a constitutively low birth weight.
Because previous studies showed that vascular reactivity varies along the umbilical cord (23), we
decided to focus on the segment closer to the fetus. The umbilical cord was cut as close as possible
to the fetus and a ~10-cm segment was put into a deoxygenated physiological solution and kept at
4°C until dissection. This “fetal” segment was then used as followed: the portion near the fetus was
dissected and used for pharmacological testing of the vessels. The following portion was dissected
to separate the vein and the arteries from the Wharton’s jelly in order to perform RNA and protein
expression analyses. Finally a 1-cm segment was harvested for histological analyses. 
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Western Blot
Umbilical veins were crushed using a cryogenic mortar, and homogenized in a lysis buffer (50 mM
HEPES,  1  mM EDTA,  1  mM EGTA,  10% glycerol,  1  mM DTT,  5  mg/ml  pepstatin,  3  mg/ml
aprotinin,  10  mg/ml leupeptin,  0.1 mM AEBSF, 1 mM sodium vanadate,  50 mM NaF,  20 mM
CHAPS). After a 10min centrifugation (3’000 x g, 4°C) to discard insoluble material, total protein
concentration in tissue homogenates was quantified using BCA protein assay (Pierce). For each
group (IUGR and control), samples from 40 patients were randomly distributed in four pools, by
mixing an equal amount of proteins (100μg) from every sample. This allows to average individual
variability inside every pool and to focus on the main differences between IUGR and controls.
Conditions used for Western Blotting experiments are summarized in Table 1.
Protein
Amount of protein
(μg)
Acrylamide gel
concentration
Primary antibody
concentration
Primary antibody
make
eNOS 60 7.5% 1/200
BD Transduction
Laboratories
Caveolin 20/40 7.5%/12.5% 1/4000
BD Transduction
Laboratories
sGC 40 7.5% 1/500 Cayman
PDE5a 40 7.5% 1/250 Santa Cruz
Actin - - 1/250 Sigma
Migration was performed during 35 minutes at 200V, followed by transfer during 2 hours at 100V.
Then, the membrane was blocked overnight in a solution containing casein. The membrane was
then washed in TBST and incubated 1 hour with the primary antibody diluted in a casein solution.  
After another wash with TBST, the membrane was incubated 30min in a 1/2000 biotinylated anti-
rabbit  secondary  antibody  solution,  re-washed  in  TBST  and  incubated  30min  with  avidin-
peroxydase (Vectastain). After a last wash, the membrane was incubated 5min with ECL (Thermo
Scientific) and images were taken with a LAS-4000 image reader (Fujifilm). Exposure time varied
between different membranes, even for the same protein, depending on the intensity of the signal.
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Table 1: Conditions used to detect the studied proteins by Western Blot
Then, actin content was assessed on each membrane to control for protein amount, using the same
protocol  as  above,  but  with  a  primary  antibody  concentration  of  1/250  and  using  a  classical
peroxidase-linked  secondary  antibody  at  a  concentration  of  1/10'000  instead  of  a  biotinylated
secondary antibody. Since actin expression is relatively constant in a given tissue, it can be used to
normalize intensity observed for the protein of interest,  to correct for potential variations in the
protein amount charged on the gel, due for example to possible imprecision in pipeting or protein
quantification. 
The images were analyzed using the ImageJ software to determine the intensity of each band. The
band intensity of the protein of interest was divided by the intensity of the corresponding actin band
to normalize the results. For each protein of interest, at least four Western Blots were performed. To
normalize for differences between membranes, like exposure time or efficiency of immunoblotting,
this  ratio  was  not  expressed  as  an  absolute  value,  but  relatively to  the  protein/actin  ratio  of  a
predetermined "reference pool" chosen among the control pools.
For each pool, the average protein content of 4 or 6 membranes was calculated. Then the average
protein content was calculated for the IUGR group and the control group, as well as their standard
deviation. These two averages were then compared by a Student's t test.
9/29
Immunohistochemistry
The umbilical cord's segment used for histological analysis was dehydrated by successive baths in
increasing concentrations of ethanol, then incubated in xylene and finally paraffin to obtain paraffin
blocks.  Sections  of  5μm  were  cut  using  a  microtome  and  fixed  onto  microscope  slides.
Immunostaining was performed on histological sections to determine tissular localization of  the
tested proteins, namely eNOS, sGC and PDE5a.
Slides carrying the sections were washed in xylene, decreasing concentrations of ethanol and finally
in water in order to eliminate paraffin and rehydrate the tissues. Slides were then incubated in
boiling citrate buffer for 3x5 minutes in order to unmask antigenic sites. After washing (all washes
were performed in a PBS 0.5% Triton X-100 solution), slides were incubated with 1.5% goat serum
diluted in PBS. Since the secondary antibody was produced in goat, this step was performed to
block all sites, which could have a non-specific affinity for the secondary antibody and therefore
give rise to a non-specific signal, yielding a strong background staining. After a brief wash, slides
were then covered overnight with the primary antibody diluted in PBS buffer. The concentration of
the different antibodies were as follows:
• eNOS 1/200 (BD Transduction Laboratories)
• sGC 1/100 (Cayman)
• PDE5a 1/100 (Santa Cruz)
After a new wash, the slides were incubated for 1 hour with the secondary biotinylated anti-rabbit
antibody diluted in a PBS buffer, followed by another wash and a 1 hour incubation with avidin-
peroxydase (Vectastain). The slides were washed again and then incubated for 30 min with Vector
Red  (Vectastain).  After  a  last  wash,  slides  were  dehydrated  by  successive  baths  in  increasing
concentrations of ethanol and finally xylene,  before fixation with Eukitt® resin.  The slides were
visualized with a fluorescence microscope (Leica).
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Results 
The demographic data related to the population studied in the present report are summarized in 
Table 2. Gestational age at birth, as well as maternal age are similar in the IUGR and the control 
group. Birth weight, size, head circumference, placental weight and umbilical cord diameter were 
significantly lower in the IUGR group compared to controls. Furthermore, an intrauterine growth 
curve break was confirmed by the prenatal data in about 70% of the individuals of our IUGR group,
therefore confirming IUGR status, versus a constitutively small birth weight.
GIRLS CTRL IUGR p-value
Number of patients included 40 40
Gestational age (weeks) 39.6  0.9 39.4  1.0 0.2309
Birth weight (g) 3366  285 2617  242 * <0.0001
Size (cm) 49.4  1.6 46.4  1.7 * <0.0001
Head circumference (cm) 34.6  1.1 32.7  1.1 * <0.0001
Placental weight (g) 638  135 452  75 * <0.0001
Umbilical cord diameter (mm) 12.2  2.3 10.9  2.4 * 0.0104
Maternal age (years) 31.6  5.8 30.5  5.0 0.3551
The results obtained in the Western Blotting and immunostaining experiments are presented below
for each protein of interest.
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Table 2:  Demographic data of newborn girls providing the umbilical cords used for the Western
Blots. Data are expressed as mean ± SD. * Statistical difference between both groups (p< 0.05,
Mann-Whitney test).
1) eNOS
Western Blot
Four Western Blots were performed for eNOS. The ratio between eNOS band intensity and actin
band intensity was determined for each pool and expressed relatively to the ratio of pool C on each
of the four membranes (Fig.1). The average value of the four membranes was calculated for each
pool. With these values, the mean and the standard deviation were calculated for the control group
(four pools) and the IUGR group (four pools). The calculated mean protein content, normalized by
actin, was about 2.5 times higher in IUGR pools than in controls (p<0.05) (Fig.2).
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Figure  2:  Relative  eNOS  protein  expression  in  human
umbilical  veins  of  growth-restricted  and  control  newborn
girls. Data represent mean ± SD (n=4 pools of 10 patients
for  each  group).  *  A  significant  difference  was  found
between  control  and  IUGR  group  (p<0.05,  unpaired
Student’s t test).
*
Figure 1: eNOS Western Blot with 60μg of proteins and 1/200 primary
antibody concentration
Immunohistochemistry
eNOS immunostaining was performed on six histological sections, respectively three controls and
three IUGR. Images were taken with a magnification of 100X. eNOS immunostaining was not only
observed in the endothelium, but also in the smooth muscle and Wharton's jelly.  Although signal
intensity was slightly variable between sections of a same group, there was no significant difference
observed in intensity or distribution of fluorescence in the arteries or in the veins between both
groups. However, there was a much higher signal in Wharton's jelly of the control group than in the
Wharton's jelly of the IUGR group.
Figure  3  shows  vessels  and  Wharton's  jelly  of  two  sections,  respectively  one  from a  control
umbilical cord and one from an IUGR umbilical cord. These two sections are representative of most
sections from each group.
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Figure 3: 
Images A and B show eNOS
distribution in umbilical
vein, respectively in a control
section (A) and in an IUGR
section (B). 
Images C and D show eNOS
distribution in the Wharton's
jelly, respectively in a
control section (C) and in an
IUGR section (D)
Sections were incubated
overnight with a 1/200
primary antibody solution.
*: Lumen
+: Endothelium
I: External circular
muscular layer
+
IUGRCTRL
A
C
B
*
*
+
D
2) Caveolin
Western Blot
Six Western Blots were performed for caveolin. Four of them in a 12% acrylamide gel with 20μg
proteins from each pool, and two of them in a 7.5% acrylamide gel with 40μg proteins from each
pool. The ratio between caveolin band intensity and actin band intensity was determined for each
pool and expressed relatively to the ratio of pool C on each of the six membranes (Fig.4). The
average value of the six membranes was calculated for each pool. With these values, the mean and
the standard deviation were calculated for the control group (four pools) and the IUGR group (four
pools). The calculated mean protein content, normalized by actin, was very similar between the
IUGR group and the control group (p=0.85) (Fig.5).
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Figure  4: Caveolin  Western  Blot  with  40μg  of  proteins  and  1/4'000
primary antibody concentration
Figure  5: Relative  caveolin  protein  expression   in  human
umbilical veins of growth-restricted and control newborn girls.
Data represent mean ± SD (n=4 pools of 10 patients for each
group).  No  significant  difference  was  found  between  both
groups.
3) sGC
Western Blot
Six Western Blots were performed for sGC. The ratio between sGC band intensity and actin band
intensity was determined for each pool and expressed relatively to the ratio of pool A on each of the
six membranes (Fig.6). The average value of the six membranes was calculated for each pool. With
these values, the mean and the standard deviation were calculated for the control group (four pools)
and the IUGR group (four pools). The calculated mean protein content, normalized by actin, was
about twice as high in the IUGR group as in the control group (p<0.05) (Fig.7).
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Figure 7: Relative sGC protein expression in human umbilical
veins  of  growth-restricted  and  control  newborn  girls.  Data
represent  mean  ±  SD  (n=4  pools  of  10  patients  for  each
group). * A significant difference was found between control
and IUGR group (p<0.05, unpaired Student’s t test).
*
Figure 6: sGC Western Blot with 40μg of proteins and 1/500 primary
antibody concentration
*
Immunohistochemistry
sGC immunostaining was performed on ten histological sections, respectively five controls and five
IUGR. Images were taken with a magnification of 100X. Signal was found in the endothelium, the
smooth  muscle,  and  weakly  in  the  Wharton's  jelly  (Fig.8).  Signal  intensity  appeared  to  vary
between sections of a same group and therefore no difference could be observed in intensity or
distribution between the IUGR and the control group.
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Figure 8:
Images A and B show sGC
distribution in umbilical vein,
respectively in a control
section (A) and in an IUGR
section (GB. 
Images C and D show sGC
distribution in the Wharton's
jelly, respectively in a
control section (C) and in an
IUGR section (D)
Sections were incubated
overnight with a 1/100
primary antibody solution.
*: Lumen
+: Endothelium
I: External circular muscular
layer
IUGRCTRL
A
C
B
+
+
*
*
D
4) PDE5a
Western Blot
Six Western Blots were performed for PDE5a. The ratio between PDE5a band intensity and actin
band intensity was determined for each pool and expressed relatively to the ratio of pool B on each
of the six membranes (Fig.9). The average value of the six membranes was calculated for each pool.
With these values, the mean and the standard deviation were calculated for the control group (four
pools)  and  the  IUGR  group  (four  pools).  One  membrane  was  excluded  because  of  its
inhomogeneous actin  bands,  of  which some were almost  absent,  probably because of technical
problems during transfer or blotting. The calculated mean protein content, normalized by actin, was
significantly lower in IUGR group compared to controls (p<0.05) (Fig.10). However, these results
should be considered with caution, as a lack of reproducibility in staining between membranes led
to an important variability of ratios of a same pool between the different membranes.
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Figure 9: PDE5a Western Blot with 40μg of proteins and 1/250 primary
antibody concentration 
Figure  10: Relative  PDE5a  protein  expression  in  human
umbilical veins of growth-restricted and control newborn girls.
Data represent mean ± SD (n=4 pools of 10 patients for each
group).  *  A  significant  difference  was  found  between  both
groups (p<0.05, unpaired Student’s t test)
*( )
Immunohistochemistry
PDE5a immunostaining was performed on ten histological sections, respectively five controls and
five IUGR. Images were taken with a magnification of 100X. Signal was found in the endothelium
and the smooth muscle, but was almost absent in the Wharton's jelly (Fig11).  The signal in some
sections was very weak. Therefore it  was difficult  to observe differences between both groups.
However we observed a difference between the two arteries of a same section in the control group.
Indeed in 4/5 sections in the control group, one of the arteries had a stronger signal than the other.
The one exception was a section on which none of the two arteries was marked.
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Figure 11:
Images A and B show
PDE5a distribution in
umbilical vein, respectively
in a control section (A) and
in an IUGR section (B). 
Images C and D show
PDE5a distribution in the
Wharton's jelly,
respectively in a control
section (D) and in an IUGR
section (H)
Section were incubated
overnight with a 1/100
primary antibody solution.
*: Lumen
+: Endothelium
I: External circular
muscular layer  
A
C
B
* *+ +
D
IUGRCTRL
Discussion
This  project  aimed  to  better  understand  modifications  occurring  in  the  regulation  of  umbilical
circulation  in  growth-restricted  neonates.  As  pharmacological  experiments  showed  a  decreased
NO-induced relaxation in isolated umbilical veins of newborn girls with IUGR, we investigated the
expression of several proteins implicated in the NO/cGMP-mediated relaxation.
The first tested protein was the endothelial NO synthase (eNOS) which produces the vasorelaxant
agent NO. Our results showed that eNOS protein content was about 2,5 times higher in IUGR veins
than in control veins.
This increase in eNOS protein content would contribute to facilitate relaxation, as the production of
NO  would  be  increased.  This  result  is  nevertheless  compatible  with  the  preliminary
pharmacological  experiments  which showed a decreased NO-induced relaxation in  IUGR veins
compared to controls, since in these experiments, isolated veins were exposed to cumulative doses
of a  NO donor in the presence of a  NOS inhibitor.  They therefore give no information on the
quantity of NO produced in IUGR or control veins.
eNOS immunostaining was not only found in the endothelium, but also in the smooth muscle and in
the Wharton's jelly of umbilical veins. A similar distribution is reported by Mauro et al (24), who
described eNOS immunostaining in the endothelium and in the Wharton's jelly, but did not mention
a signal in the smooth muscle. 
Remarkably, the only difference observed between histological sections from IUGR and control
group was not the increased protein content in IUGR veins revealed by the  Western Blot, but an
increased  immunostaining  signal  in  the  Wharton's  jelly  of  the  IUGR group.  Nevertheless,  this
observation should be considered with caution as immunostaining is not an appropriate method to
assess protein content of a tissue. Therefore these observations should absolutely be confirmed by
Western Blot before being considered as interpretable.
Immunostaining did not allow to determine the signal distribution in the Wharton's jelly, since the
signal was too weak to show images at a higher magnification.
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There are some controversies in the literature on eNOS protein content and activity in the human
umbilical  vein  in  IUGR.  Some  report  a  reduced  eNOS protein  content  and activity  in  human
umbilical  vein  endothelial  cells  (HUVEC)  (25,26),  while  others  point  out  an  increased  eNOS
protein content and activity for infants with birth weights below the 25th  percentile, this effect being
maximal between the 3th and the 10th percentile, a population which is considered as IUGR in our
study (27). Furthermore, some other studies report an increased eNOS protein content in IUGR
HUVEC, but a decreased activity of this  protein,  resulting in lower cGMP concentrations (28).
Nevertheless,  these  experiments  considered  only  endothelial  cells.  Our  immunostaining
experiments showed that eNOS is also present in the smooth muscle. Therefore our Western Blot's
results cannot directly be compared to those of other studies. It would however be interesting to
assess whether this eNOS increase is predominant in the smooth muscle or in the endothelial cells.
A reliable method would be a cell culture of endothelium and smooth muscle cells from IUGR and
control veins, to assess by Western Blot in which tissue eNOS protein content is increased.
Moreover,  eNOS  activity  can  be  regulated  by  many  ways,  such  as  activating  or  inhibiting
phophorylations, or intracellular calcium (29). Thus, the measured protein content does not provide
information about the in-vivo activity modulation of eNOS.
Furthermore, other isoforms of NOS, like inductible NOS or neural NOS, should be tested, since
these isoforms can be expressed in several different tissues. These isoforms could replace each other
in pathological condition (30). Indeed, iNOS expression has been shown to be present in HUVEC
and its expression seems to be increased in IUGR (24,27).
To assess the real NO production of eNOS, subjected to its different regulations, eNOS activity
should be  measured with  a  blocking,  if  possible,  of  the  other  NOS isoforms.  However,  this  is
technically difficult because of the high instability and reactivity of gaseous NO. Another way to
evaluate eNOS activity would be to determine by Western Blot the proportion of activated eNOS
protein, which is phosphorylated on a specific serine residue (29).
It is also important to notice that independently of its production, NO quantity can be altered by the
presence of reactive oxygen species (ROS), as they degrade NO. Hypoxic conditions, as they are
present in the feto-placental circulation of a growth-restricted fetus, are known to favor formation of
such ROS in the mitochondria (31,32). Considering that mitochondria undergo several alterations in
IUGR (33,34,35), it could be conceivable that these changes have an influence on the presence of
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ROS. 
The second protein we studied was caveolin, a small membrane protein involved in the formation of
caveolae. Caveolae correspond to invaginations of the plasma membrane, present for example in
endothelial cells, which concentrate numerous membrane proteins implicated in cellular trafficking
and signaling, like eNOS. In these caveolae, eNOS is bound, and so inhibited by caveolin until a
rise in intracellular calcium levels allows the calcium/calmodulin complex to displace caveolin and
to free eNOS from its repression (29). Therefore a change in caveolin expression could influence
the activity of eNOS and hence affect vasoreactivity. The Western Blots in our experiments showed
no  difference  in  caveolin  protein  content  between  IUGR  and  control  umbilical  veins.  This
observation was reproducible across all our membranes.
The third protein we investigated was sGC, which, when stimulated by NO, produces cGMP and
thus promotes smooth muscle relaxation and so vasodilatation. sGC protein content was found to be
approximately twice as high in IUGR umbilical veins compared to controls. Since this difference
occurs  to  be consistently observed throughout  all  our  six membranes,  this  result  appears  to  be
reliable. Such an increase should favor the NO-induced relaxation in the IUGR veins.
This  result  is  surprising  because  pharmacological  studies  showed  a  decreased  NO-induced
relaxation in isolated umbilical veins of IUGR newborn girls. However, there are different ways to
explain these apparently contradictory results. 
First,  as discussed for eNOS, protein activity can be modulated by several factors (36) so that
increased protein content does not necessarily result in higher protein activity. Interestingly, several
molecules proposed to reduce sGC activity, as hydrogen peroxide or superoxide, are ROS, which
could be increased in IUGR as discussed above. An appropriate method to have an overview of sGC
activity would be to measure the cGMP production by ELISA, in the presence of an inhibitor of
phosphodiesterases (PDE), which degrade cGMP.
Second, the decreased NO-induced relaxation observed in the pharmacological studies could be due
to downstream alterations of the NO/cGMP pathway, for example at the level of PKG or below.
In this case, the observed sGC increase would be a counteracting mechanism to compensate for this
alteration.
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Third,  a  parallel  increase  of  the  cGMP degrading  enzymes  PDEs  would  also  be  conceivable,
counteracting the higher cGMP production by sGC and resulting in an unchanged or even decreased
cGMP amount.
It  is  interesting  to  note  that  Steinert  et  al  found no significant  change in  sGC protein  content
between HUVEC from babies born preterm or from a preeclampsia affected mother, and controls
(37).  Nevertheless,  babies  born  preterm are  not  necessarily  growth-restricted,  and even  though
preeclampsia is a major cause of IUGR, no indication of birth-weight was precised. Moreover, only
endothelial cells were studied while we studied the whole vein.
Immunohistochemistry did not point out the difference shown by the Western Blot.  Signal was
found in the endothelium and the smooth muscle but no real difference between IUGR and control
sections could be observed. It is interesting to notice that signal intensity was somewhat variable
between  the  five  sections  of  a  same  group.  Such  variations  could  be  due  either  to  technical
problems or more likely to interpersonal variability. Indeed in the Western Blot we tested pools
composed  of  umbilical  veins  homogenates  from  ten  different  individuals,  whereas  in  the
immunostaining experiments each section corresponds to one individual.
The fourth and last tested protein was PDE5a. Phosphodiesterases (PDEs) are a group of enzymes
degrading cyclic nucleotide second messengers, like cGMP or cAMP. The specificity for one or the
other  of these two molecules depends on the PDE subfamily.  We decided to  focus  on PDE5a,
because the PDE5 subfamily has a high affinity for cGMP and thus plays an important role in
smooth muscle.
Our Western Blot's results showed a slight decrease in PDE5a protein content in the IUGR group
compared  to  controls.  Nevertheless,  this  result  should  be  considered  with  great  caution  as
reproducibility  between  different  membranes  was  problematic.  Consequently,  p-value  was  only
little below 0.05 (p=0.0435) and only when certain pools where chosen as reference pools.
The encountered technical problems could be due to some properties of the used antibody. Another
antibody against the same protein should be tested to see whether it would give more reproducible
results. Nevertheless the results, even though it should be emphasized that they are not that reliable,
will  be  analyzed  and  discussed  in  the  following  lines.  Further  experiments  using  for  example
another antibody, or qPCR to measure mRNA content, should contribute to confirm or infirm them.
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The observed slight decrease in PDE5a protein content in IUGR group compared to controls does
not  explain  the observations  made in  the  pharmacological  experiments.  Indeed a  lower  PDE5a
protein content would have pro-relaxing effects, since it would increase the half-life of the pro-
relaxing second messenger cGMP. But, as it is the case for the other tested proteins, PDE5a activity
can  be  modulated  in  different  ways.  Indeed,  it  has  been  shown  that  PDE5  activity  is  highly
increased when cGMP is bound. These observations were made in vitro, and as PDE5a has a very
high affinity for cGMP, it is likely that PDE5a is fully activated by cGMP in vivo. There is also
evidence that  PDE5a phosphorylation by PKG can stabilize cGMP binding and therefore yield
higher activity, resulting in a negative feedback loop. It is furthermore interesting to note that cGMP
can also modulate other PDE subfamilies, which are more specific to cAMP. By this way, cGMP
could affect cAMP level in the cell, which is also implicated in the smooth muscle tone regulation
(38).
Thus, to have a more complete view of PDEs presence and activity in the cells, other isoforms and
other subfamilies should be tested, as they could compensate for the PDE5a deficit. To evaluate the
contribution of each subfamily, cGMP degradation could be measured using a fluorescent ELISA in
the presence of selective inhibitors of a different PDEs.
Furthermore it would be interesting to assess changes in cAMP quantity, which would also have an
influence on smooth muscle tone.
Interpretation of immunohistological results was complicated for PDE5a, as many sections had an
extremely low signal, especially in the IUGR group. This could be due to the lower PDE5a protein
content  in  the IUGR sections,  but  as  the used antibody is  probably problematic,  as  mentioned
before, this seems to be a much more likely cause of the staining problems. Again, it would be
interesting  to  repeat  this  experiment  with  another  anti  PDE5s  antibody,  and maybe  a  positive
control to assess whether the absence of signal is due to technical problems or little protein content.
Because of this very poor staining, no conclusion can be drawn regarding the possible differences of
distribution or intensity between IUGR and controls.
In summary, our results show that in growth-restricted female human umbilical vein, eNOS and
sGC protein content is increased, while PDE5a protein content seems to be decreased compared to
controls. Caveolin protein content was unchanged between the two groups. Immunostaining did not
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point out a difference in distribution of our tested proteins between IUGR and control groups, but
suggest  that  eNOS content  in the IUGR Wharton's  jelly could be increased.  Both observations
should absolutely be confirmed by Western Blot,  as immunostaining is  a  qualitative method to
assess signal localization, but not a quantitative method allowing to reliably assess protein content.
This  is  also  the  most  likely reason why our  immunostaining  data  does  not  correlate  with  our
Western Blot's result.
In general, it is important to note that a higher specific protein content does not necessarily result in
a higher activity, since the different proteins can be regulated in different ways, as discussed above
for each protein. But interestingly, all the protein expression alterations we observed should favor
NO/cGMP-mediated relaxation by increasing the cGMP level in the smooth muscle cell. However,
this is not what was observed in the pharmacological experiments, which showed a decreased NO-
induced  relaxation.  It  is  therefore  likely  that  these  pro-relaxing  alterations are  a  response  to
compensate for a decreased relaxation ability of the IUGR veins, probably due to other alterations
elsewhere in the pathway. 
Further experiments will therefore have to assess the consequence of the observed protein content
alterations on cGMP level. This second messenger was reported to be decreased in IUGR HUVEC
(28) but increased in preeclampsia HUVEC (37). It would be interesting to assess cGMP level in the
smooth muscle where it can yield relaxation. Therefore separate cell cultures of endothelium and
smooth muscle cells would be useful. These could also be used to assess whether the alterations we
described above are present predominantly in the endothelium, in the smooth muscle or in both of
these tissues. Other isoforms of the tested proteins should be tested too, as these could replace each
other and assume their function, and thus affect cGMP levels. Moreover, other potential alterations
further downstream in the pathway should be investigated. The first of them would be PKG which,
when activated by cGMP, affects intracellular calcium levels and membrane polarisation and thus
promotes relaxation. It would also be interesting to assess possible changes in myosin light chain
kinase phosphorylation, secondary to PKA activity regulated by cAMP level, which is dependent,
among others, of PDE activity. Other vasorelaxation-inducing pathways, as the prostaglandin or the
EDHF pathways, should be investigated too. 
Furthermore it would be interesting to assess if such alterations of relaxation pathways are also
present  in  the  umbilical  arteries  of  growth-restricted  individuals,  giving  an  insight  of  possible
general changes in the organism's vessels, which could contribute to development of cardiovascular
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disease  much  later  in  life.  Umbilical  vessels  from  male  newborn  boys  should  be  tested  too.
Additionally,  the  contraction  pathways  should  also  be  tested  in  umbilical  veins  and  arteries.
Alteration in structure, composition and protein expression in the Wharton's jelly could also have an
influence on the reactivity of umbilical vessels and should therefore be tested.
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